Literature DB >> 11105940

Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression.

S M Ferguson1, J D Brodkin, G K Lloyd, F Menzaghi.   

Abstract

RATIONALE: Epidemiological studies of smokers suggest that there is a link between nicotine and depression. Nonetheless, few studies have examined the potential use of nicotinic ligands in the treatment of depression.
OBJECTIVES: The goal of this study was to evaluate the effects of SIB-1508Y, a novel subtype-selective ligand for high affinity nicotinic acetylcholine receptors (nAChRs), in the learned helplessness model of depression in rats.
METHODS: In this model, exposure to inescapable foot-shock produces a lasting deficit in escape responses emitted in a subsequent conditioned avoidance procedure (learned helplessness). The effect of SIB-1508Y on learned helplessness was compared to the clinically used antidepressants, imipramine and fluoxetine, and the non-selective nAChR ligand, nicotine.
RESULTS: Similarly to imipramine and fluoxetine, subchronic treatment (5 days) with SIB-1508Y reversed the escape deficit in the learned helplessness model in a dose dependent manner. The effect of SIB-1508Y on learned helplessness was still apparent 1 week following drug administration and was also maintained after 4 weeks of daily administration. In contrast, while nicotine was able to attenuate the learned helplessness deficit, this trend only reached statistical significance after chronic administration. The non-competitive ion channel blocker mecamylamine increased escape failures when administered alone and blocked the effects of SIB-1508Y but not imipramine. SIB- 1508Y also produced an increase in avoidance responding, which suggests an enhancement of learning.
CONCLUSION: These results not only suggest a role for nAChRs in the development of a depressive-like syndrome, but also that subtype-selective nAChR agonists, such as SIB-1508Y, may offer a novel therapeutic approach to the treatment of depression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11105940     DOI: 10.1007/s002130000531

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  31 in total

Review 1.  Examining antidepressant drug response by smoking status: why is it important and how often is it done?

Authors:  Andrea H Weinberger; Sherry A McKee; Marina R Picciotto; Carolyn M Mazure
Journal:  J Psychopharmacol       Date:  2010-12-17       Impact factor: 4.153

2.  Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial.

Authors:  F Joseph McClernon; F Berry Hiott; Eric C Westman; Jed E Rose; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2006-09-15       Impact factor: 4.530

3.  Social defeat, a paradigm of depression in rats that elicits 22-kHz vocalizations, preferentially activates the cholinergic signaling pathway in the periaqueductal gray.

Authors:  Roger A Kroes; Jeffrey Burgdorf; Nigel J Otto; Jaak Panksepp; Joseph R Moskal
Journal:  Behav Brain Res       Date:  2007-03-25       Impact factor: 3.332

4.  Evidence for the involvement of NMDA receptors in the antidepressant-like effect of nicotine in mouse forced swimming and tail suspension tests.

Authors:  Arya Haj-Mirzaian; Nastaran Kordjazy; Arvin Haj-Mirzaian; Sattar Ostadhadi; Mehdi Ghasemi; Shayan Amiri; Mehrdad Faizi; AhmadReza Dehpour
Journal:  Psychopharmacology (Berl)       Date:  2015-07-15       Impact factor: 4.530

5.  The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice.

Authors:  R L Rabenstein; B J Caldarone; M R Picciotto
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

6.  Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior.

Authors:  Jill R Turner; Laura M Castellano; Julie A Blendy
Journal:  J Pharmacol Exp Ther       Date:  2010-04-30       Impact factor: 4.030

Review 7.  The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited.

Authors:  Jordy van Enkhuizen; David S Janowsky; Berend Olivier; Arpi Minassian; William Perry; Jared W Young; Mark A Geyer
Journal:  Eur J Pharmacol       Date:  2014-08-05       Impact factor: 4.432

Review 8.  Future antidepressants: what is in the pipeline and what is missing?

Authors:  Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 9.  Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

10.  Antidepressant-like effects of nicotine and transcranial magnetic stimulation in the olfactory bulbectomy rat model of depression.

Authors:  Patricia Vieyra-Reyes; Yann S Mineur; Marina R Picciotto; Isaac Túnez; Román Vidaltamayo; René Drucker-Colín
Journal:  Brain Res Bull       Date:  2008-06-26       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.